Friday, 19 Oct 2018

You are here

Bone Marrow Edema May be Found in Normals, Athletes and Military Recruits

Rheumatology has published a study demonstrating that bone marrow edema as measured by magnetic resonance imaging (MRI) may be found in healthy people, but that such changes do not change with intense physical activity. (Citation source https://buff.ly/2CvbuXD)

These findings are notable in light of recent reports from the ACR 2017 meeting showing that bone marrow edema was  commonly seen in the SI joints of athletes (Abstract #1830) and that MRI evidence of bone marrow edema in the SI joints is not specific for axial spondyloarthritis  (Abstract #1831).

In the current observational study, 22 military recruits underwent an MRI of the SI joints before and after 6 weeks of intense standardized physical training. Bone marrow edema and structural lesions were scored based on the Spondyloarthritis Research Consortium of Canada (SPARCC) method. 

At the beginning, 40.9% of recruits already presented a SPARCC score indicating bone marrow edema; this number showed a nonsigificant increase to 50% after six weeks.  Similarly, the number of positive MRI by ASAS definition was not significantly different in the two time points. 

They found no relationship between symptoms of back pain and bone marrow edema lesions.

The study underscores the necessity to interpret MRI findings of the sacroiliac joints in the appropriate clinical context, even in a young active population.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Predictive Risk Factors for Uveitis in JIA

Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.

Elder Rheumatoids Less Likely to Receive Biologics

Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients. Now a VAMC study shows that the elderly are less likely to receive biologic agents yet are as likely to be subjected to glucocorticoid use.

Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.

Defining Refractory Rheumatoid Arthritis

Researchers from the British Society for Rheumatology Biologics (BSRBR) set out to define under what circumstances will rheumatoid arthritis (RA) patients manifest biologic disease-modifying antirheumatic drugs (bDMARDs) refractory disease.

Using the patients from the BSRBR Register (2001 to 2014) they defined patients as bDMARD refractory when they initiated their third class of bDMARD.

Venous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition

Venous thromboembolism (VTE) is a common adverse event throughout medicine and includes both pulmonary embolism (PE) and deep vein thrombosis (DVT).   The cost of diagnosing a thromboembolic event is approximately $4000 - $5550, while the annual cost of treating one case of VTE is between $17,000 and $19,000. The impact of VTE is substantial.